Breaking Down SG&A Expenses: AbbVie Inc. vs Galapagos NV

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. AbbVie Inc. and Galapagos NV, two prominent companies, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. AbbVie, a giant in the sector, has seen its SG&A expenses grow by approximately 66%, peaking in 2022. This reflects its aggressive expansion and marketing strategies. In contrast, Galapagos NV, a smaller player, has maintained a more conservative approach, with its SG&A expenses increasing by about 250% over the same period, albeit from a much smaller base. This divergence highlights the different growth strategies and market positions of these companies. As the industry evolves, monitoring these financial metrics will provide insights into their future trajectories.